Literature DB >> 10730903

Prostate cancer: molecular biology of early progression to androgen independence.

M D Sadar1, M Hussain, N Bruchovsky.   

Abstract

To improve the therapy for prostate cancer, it will be necessary to address the problems of progression to androgen independence and the process of metastatic spread of tumour. The complexity of the latter condition is likely to mitigate against the immediate development of relevant therapeutic approaches. However, the basis of androgen independence appears to be a problem of simpler dimensions and more amenable to treatment with current therapeutic technology. Since early tumour progression can be detected by an incomplete prostate-specific antigen (PSA) response to androgen withdrawal therapy, a study of the molecular biology of PSA gene regulation may well provide insight into new methods for preventing or delaying this problem. Mounting evidence suggests that ligand-independent activation of the androgen receptor may be one underlying mechanism of androgen independence. In the absence of androgen, a compensatory increase in the activity of cAMP-dependent protein kinase (PKA) enhances the ability of the androgen receptor to bind to the response elements regulating PSA gene expression. The activation of the androgen receptor through up-regulation of the PKA signal transduction pathway involves the amino-terminus of the androgen receptor, the function of which may be altered either by modifications such as phosphorylation, or through interactions with co-regulators or other proteins. Of therapeutic interest is the fact that this effect can be counteracted experimentally by the anti-androgen, bicalutamide, and clinically by several other similar agents. We speculate that the inhibition of PKA-activated androgen receptor might also be accomplished by decoy molecules that can bind to the relevant activated site on the amino-terminus or competitively interact with proteins recruited by the PKA pathway that are responsible for activating the receptor in the absence of androgen. Such molecules might include small mimetic substances or agents that can gain access to the nucleus of the cell.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10730903     DOI: 10.1677/erc.0.0060487

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  30 in total

1.  Androgen receptor decoy molecules block the growth of prostate cancer.

Authors:  Steven N Quayle; Nasrin R Mawji; Jun Wang; Marianne D Sadar
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-16       Impact factor: 11.205

2.  Molecular alterations in primary prostate cancer after androgen ablation therapy.

Authors:  Carolyn J M Best; John W Gillespie; Yajun Yi; Gadisetti V R Chandramouli; Mark A Perlmutter; Yvonne Gathright; Heidi S Erickson; Lauren Georgevich; Michael A Tangrea; Paul H Duray; Sergio González; Alfredo Velasco; W Marston Linehan; Robert J Matusik; Douglas K Price; William D Figg; Michael R Emmert-Buck; Rodrigo F Chuaqui
Journal:  Clin Cancer Res       Date:  2005-10-01       Impact factor: 12.531

3.  GPRC6A regulates prostate cancer progression.

Authors:  Min Pi; L Darryl Quarles
Journal:  Prostate       Date:  2011-06-16       Impact factor: 4.104

4.  Positron tomographic assessment of androgen receptors in prostatic carcinoma.

Authors:  Farrokh Dehdashti; Joel Picus; Jeff M Michalski; Carmen S Dence; Barry A Siegel; John A Katzenellenbogen; Michael J Welch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-02-22       Impact factor: 9.236

5.  Inhibition of androgen receptor-mediated transcription by amino-terminal enhancer of split.

Authors:  X Yu; P Li; R G Roeder; Z Wang
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

6.  Antibody Microarray Analysis of Signaling Networks Regulated by Cxcl13 and Cxcr5 in Prostate Cancer.

Authors:  Christelle P El-Haibi; Rajesh Singh; Pranav Gupta; Praveen K Sharma; Krysta N Greenleaf; Shailesh Singh; James W Lillard
Journal:  J Proteomics Bioinform       Date:  2012

7.  Treatment of prostate cancer cells with adenoviral vector-mediated antisense RNA using androgen-dependent and androgen-independent promoters.

Authors:  Wei Li
Journal:  Med Oncol       Date:  2009-06-11       Impact factor: 3.064

8.  Analysis of the molecular networks in androgen dependent and independent prostate cancer revealed fragile and robust subsystems.

Authors:  Ryan Tasseff; Satyaprakash Nayak; Saniya Salim; Poorvi Kaushik; Noreen Rizvi; Jeffrey D Varner
Journal:  PLoS One       Date:  2010-01-28       Impact factor: 3.240

Review 9.  Characterization of tumor differentiation factor (TDF) and its receptor (TDF-R).

Authors:  Izabela Sokolowska; Alisa G Woods; Mary Ann Gawinowicz; Urmi Roy; Costel C Darie
Journal:  Cell Mol Life Sci       Date:  2012-10-18       Impact factor: 9.261

Review 10.  A role for the androgen-receptor in clinically localized and advanced prostate cancer.

Authors:  James L Mohler
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2008-04       Impact factor: 4.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.